Edwards Lifesciences to get $4.2 billion in cash for sale of critical-care group
Edwards said it plans to use the proceeds from the sale of the business to fund investments for growth, such as in technologies for aortic, mitral, tricuspid and pulmonic patients; and therapeutic areas for interventional heart failure.
